The EIF2AK3 Knockout A2780 Polyclonal Cells provide a robust loss-of-function model created through CRISPR/Cas9-mediated disruption of the EIF2AK3 gene in A2780 cells. This polyclonal knockout population preserves genetic heterogeneity while eliminating functional PERK kinase expression, enabling comprehensive investigations into ER stress signaling and the unfolded protein response.
The parental A2780 cell line is a human ovarian carcinoma epithelial model established from an untreated patient with endometrioid adenocarcinoma. These cells harbor wild-type p53 and express progesterone receptor, and are recognized as a drug-sensitive system widely used to study ovarian cancer biology and chemotherapeutic responses.
EIF2AK3 encodes PERK (PKR-like ER kinase), a type I transmembrane sensor of endoplasmic reticulum stress. Under accumulation of unfolded proteins, BiP (GRP78) dissociation triggers PERK oligomerization and trans-autophosphorylation. Activated PERK directly phosphorylates eukaryotic initiation factor 2?? (eIF2??) at Ser51, acutely reducing global cap-dependent translation while selectively enhancing translation of ATF4. This transcription factor drives expression of genes including CHOP (DDIT3), GADD34 (PPP1R15A), and Nrf2 (NFE2L2), tipping the balance between adaptive survival and apoptosis. PERK functions in concert with IRE1?? and ATF6 within the broader integrated stress response network, and its activity is modulated by upstream signals such as hypoxia, nutrient deprivation, and oxidative stress.
In the A2780 ovarian cancer context, PERK-dependent UPR activation is critical for coping with tumor microenvironmental challenges. The loss of PERK in this p53-proficient, progesterone receptor-positive, drug-sensitive background creates a powerful system to dissect how ER stress signaling contributes to ovarian carcinoma cell fate decisions and to delineate PERK-specific roles independent of other UPR branches. This model is particularly valuable for exploring mechanisms linking ER stress to chemotherapy resistance and for testing PERK-targeted interventions.
Typical experimental applications include analyzing UPR pathway activation via western blotting for PERK, phosphorylated eIF2??, ATF4, and CHOP; RT-qPCR profiling of UPR target genes; apoptosis assays under ER stress inducers such as tunicamycin; cell viability and colony formation studies; and drug sensitivity testing with agents like cisplatin. Flow cytometric detection of phospho-eIF2?? and migration assays further support functional phenotyping. For additional guidance or lot-specific data, please contact Ascent Research.
